| Identification | Back Directory | [Name]
CDK2 INHIBITOR II | [CAS]
222035-13-4 | [Synonyms]
SC 221409
COMPOUND 3
CDK2 INHIBITOR II | [Molecular Formula]
C14H11BrN4O3S | [MDL Number]
MFCD03456380 | [MOL File]
222035-13-4.mol | [Molecular Weight]
395.23 |
| Chemical Properties | Back Directory | [Melting point ]
>272°C (dec.) | [density ]
1.85±0.1 g/cm3(Predicted) | [storage temp. ]
Amber Vial, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
8.81±0.20(Predicted) | [color ]
Light Orange to Orange |
| Hazard Information | Back Directory | [Description]
The cyclin-dependent kinase 2 (Cdk2) works with cyclins A or E to regulate S phase and G2-M transition during the cell cycle.1 Cdk2 Inhibitor II is a 3-(benzylidne)indolin-2-one analog that selectively and potently inhibits Cdk2 (IC50 = 60 nM).2 It is cell permeable, reversible, and ATP-competitive.2 | [Uses]
CDK2 inhibitor II, is a potent, cell-permeable, ATP-competitive, and selective inhibitor of Cdk2.
| [in vivo]
CDK2-IN-3 (2.5-250 μg, topical application, once daily, for 1 week) significantly reduces the incidence of alopecia in neonatal rat model induced by the combination of cyclophosphamide (HY-17420) and doxorubicin (HY-15142A)[1]. | Animal Model: | Cyclophosphamide (HY-17420)-Doxorubicin (HY-15142A) combination chemotherapy-induced alopecia neonatal Sprague-Dawley rat model (13 days) | | Dosage: | 2.5-250 μg | | Administration: | Topical application, once daily for 1 week | | Result: | Effectively prevented alopecia in 50% of rats and provided partial protection in an additional 20%. |
| [IC 50]
CDK2: 60 nM (IC50) |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|